315 af 19 254 patienter, som modtog lægemidlet, fik helvedesild i løbet af undersøgelsen sammenlignet med 642 af 19 247, som modtog placebo.
315 of the 19,254 patients who received the medicine had shingles during the study, against 642 of the 19,247 who received a placebo.